Floatz logo

Droxidopa

Multiple System Atrophy

Loma Linda UniversitySmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
89/ 100

Competitive context

26 Active assets in the Multiple System Atrophy cohort.

Asset / SponsorPhaseRating
Zoledronate
California Pacific Medical Center Research Institute
Phase 4BB
ATH-434
Alterity Therapeutics
Phase 2B
IOFLUPANE
GE Healthcare
Phase 3B
Riluzole
King's College London
Phase 3B
Fipamezole
Juvantia Pharma Ltd
Phase 2CCC

View all 40 →

Same molecule, other indications

Droxidopa is also rated in:

primary orthostatic hypotensionDormant
BBB
Indicative ·
76 / 100
View asset →
Orthostatic HypotensionDormant
BBB
Indicative ·
74 / 100
View asset →
pure autonomic failureDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →